No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings by this filer, out of 7. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.
| Company | Type | Value | Reported | Company | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | Option exercise | nothing paid20,000 shares | Sep 17, 2026 | Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | nothing paid | Option exercise | 20,000 | Sep 17, 2026 |
| Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | Open-market sell | $26,124400 shares | Sep 17, 2026 | Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | $26,124 | Open-market sell | 400 | Sep 17, 2026 |
| Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | Open-market sell | $121,0041,900 shares | Sep 17, 2026 | Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | $121,004 | Open-market sell | 1,900 | Sep 17, 2026 |
| Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | Open-market sell | $1,298,17520,735 shares | Sep 17, 2026 | Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | $1,298,175 | Open-market sell | 20,735 | Sep 17, 2026 |
| Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | Open-market sell | $1,703,24127,473 shares | Sep 17, 2026 | Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER | $1,703,241 | Open-market sell | 27,473 | Sep 17, 2026 |